Last Price | 1885.00 | Max Price | 2338.00 |
Min Price | 1794.00 | 1 Year return | 21.46 |
Sector | Health Care | Subsector | Pharmaceuticals |
Contact info:Street: 13 Hanover SquareZip Code: W1S 1HWCity: LondonCountry: Great BritainWebsite: http://www.hikma.com/
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 2,203 | 615,670 | 0.36 % |
2020 | 2,341 | 638,104 | 0.37 % |
2021 | 2,553 | 727,997 | 0.35 % |
2022 | 2,517 | 787,317 | 0.32 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The stock lost over the past 12 months at around 19 percent. Over the past 5 years Hikma Pharmaceuticals' stock lost at around 0 percent in value.
The headquarter of Hikma Pharmaceuticals is based in London. Hikma Pharmaceuticals's core business is the pharmaceutical sector. Over the past 10 years the global pharmaceutical companies gained around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
The English company didn't pay out any dividends (in the past 5 years).
At the end of 2015 the pharmaceutical company's balance sheet equaled 0 million GBp. At the end of 2015 the total debt positon equaled 0 million GBp. This is around percent of the total balance sheet.
All the company's financial reports are available here. More information about Hikma Pharmaceuticals can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
1,440
|
1,950
|
1,936
|
2,076
|
2,203
|
2,341
|
Costs |
1,188
|
1,795
|
2,779
|
1,794
|
1,717
|
1,910
|
Profit |
252
|
155
|
-843
|
282
|
486
|
431
|
Margin of profit |
17.50
|
7.95
|
-43.54
|
13.58
|
22.06
|
18.41
|
ROI |
18.85
|
6.47
|
-55.68
|
16.74
|
22.96
|
20.19
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
1,337
|
2,396
|
1,514
|
1,685
|
2,117
|
2,135
|
Debt |
1,260
|
1,967
|
1,874
|
1,812
|
1,813
|
2,000
|
Total assets |
2,597
|
4,363
|
3,388
|
3,497
|
3,930
|
4,135
|
Solvency |
51.48
|
54.92
|
44.69
|
48.18
|
53.87
|
51.63
|
Cash |
553
|
155
|
227
|
276
|
465
|
347
|
Cashflow |
366
|
293
|
443
|
430
|
472
|
464
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.29
|
0.15
|
0.24
|
0.24
|
0.26
|
0.23
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
2301.00
|
1893.00
|
1134.00
|
1716.00
|
1991.00
|
Eps |
0.66
|
-3.51
|
1.17
|
2.00
|
1.81
|
Price/earnings-ratio |
3486.36
|
-539.32
|
969.23
|
858.00
|
1041.44
|
Dividend |
0.33
|
0.34
|
0.38
|
0.47
|
0.51
|
Dividend % |
0.01 %
|
0.02 %
|
0.03 %
|
0.03 %
|
0.03 %
|
Payout % |
0.50
|
-0.10
|
0.32
|
0.23
|
0.28
|
Book value |
9.94
|
6.29
|
6.98
|
8.74
|
9.26
|
Market to book |
0.0
|
0.0
|
0.01
|
0.01
|
|
Cashflow per stock |
1.22
|
1.84
|
1.78
|
1.95
|
2.01
|
Stocks |
241
|
241
|
241
|
242
|
230
|
Market Cap |
554.541.00
|
455.605.14
|
273.809.97
|
415.819.40
|
434.413.33
|
Date
|
Price
|
---|---|
22 Apr 2025
|
1885.00
|
09 Apr 2025
|
1794.00
|
08 Apr 2025
|
1794.00
|
03 Apr 2025
|
1937.00
|
30 Mar 2025
|
1963.00
|
27 Mar 2025
|
2010.00
|
26 Mar 2025
|
2006.00
|
20 Mar 2025
|
2022.00
|
15 Mar 2025
|
2012.00
|
12 Mar 2025
|
2104.00
|
01 Mar 2025
|
2160.00
|
25 Feb 2025
|
2304.00
|
23 Feb 2025
|
2310.00
|
18 Feb 2025
|
2318.00
|
13 Feb 2025
|
2338.00
|
12 Feb 2025
|
2338.00
|
07 Feb 2025
|
2284.00
|
05 Feb 2025
|
2272.00
|
02 Feb 2025
|
2292.00
|
21 Jan 2025
|
2084.00
|
17 Jan 2025
|
2072.00
|
09 Jan 2025
|
2062.00
|
17 Dec 2024
|
1938.00
|
10 Dec 2024
|
1958.00
|
06 Dec 2024
|
1940.00
|
03 Dec 2024
|
1934.00
|
29 Nov 2024
|
1935.00
|
27 Nov 2024
|
1965.00
|
13 Nov 2024
|
1826.00
|
08 Nov 2024
|
1801.00
|